CoChat

Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups

Open access
Whitaker, Heather J., Tsang, Ruby S.M., Byford, Rachel, Andrews, Nick J., Sherlock, Julian, Sebastian Pillai, Praveen, Williams, John, Button, Elizabeth, Campbell, Helen, Sinnathamby, Mary, Victor, William, Anand, Sneha, Linley, Ezra, Hewson, Jacqueline, DArchangelo, Silvia, Otter, Ashley D., Ellis, Joanna, Hobbs, Richard F.D., Howsam, Gary, Zambon, Maria, Ramsay, Mary, Brown, Kevin E., de Lusignan, Simon, Amirthalingam, Gayatri, Lopez Bernal, Jamie · 2022 · Journal of Infection
Cited by 165

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background COVID-19 vaccines approved in the UK are highly effective in general population cohorts, however, data on effectiveness amongst individuals with clinical conditions that place them at increased risk of severe disease are limited. Methods We used GP electronic health record data, sentinel virology swabbing and antibody testing within a cohort of 712 general practices across England to estimate vaccine antibody response and vaccine effectiveness against medically attended COVID-19 amongst individuals in clinical risk groups using cohort and test-negative case control designs. Findings There was no reduction in S-antibody positivity in most clinical risk groups, however reduced S-antibody positivity and response was significant in the immunosuppressed group. Reduced vaccine effectiveness against clinical disease was also noted in the immunosuppressed group; after a second dose, effectiveness was moderate (Pfizer: 59.6%, 95%CI 18.0–80.1%; AstraZeneca 60.0%, 95%CI -63.6–90.2%). Interpretation In most clinical risk groups, immune response to primary vaccination was maintained and high levels of vaccine effectiveness were seen. Reduced antibody response and vaccine effectiveness were seen after 1 dose of vaccine amongst a broad immunosuppressed group, and second dose vaccine effectiveness was moderate. These findings support maximising coverage in immunosuppressed individuals and the policy of prioritisation of this group for third doses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jinf.2021.12.044

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 165

Metadata

Authors
Whitaker, H. J., Tsang, R. S. M., Byford, R., Andrews, N. J., Sherlock, J., Sebastian Pillai, P., Williams, J., Button, E., Campbell, H., Sinnathamby, M., Victor, W., Anand, S., Linley, E., Hewson, J., DArchangelo, S., Otter, A. D., Ellis, J., Hobbs, R. F. D., Howsam, G., Zambon, M., Ramsay, M., Brown, K. E., de Lusignan, S., Amirthalingam, G., & Lopez Bernal, J.
Venue
Journal of Infection
Publisher
Elsevier BV
Published
2022-05
Volume
84
Issue
5
Pages
675-683
ISSN
0163-4453 (ISSN-L)
OpenAlex
W4205505191
Cited by
165
References
12
FWCI
17.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. https://app.cochat.ai/papers/10.1016/j.jinf.2021.12.044
The paper
Whitaker, H. J., Tsang, R. S. M., Byford, R., Andrews, N. J., Sherlock, J., Sebastian Pillai, P., Williams, J., Button, E., Campbell, H., Sinnathamby, M., Victor, W., Anand, S., Linley, E., Hewson, J., DArchangelo, S., Otter, A. D., Ellis, J., Hobbs, R. F. D., Howsam, G., . . . Lopez Bernal, J. (2022). Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. Journal of Infection. https://doi.org/10.1016/j.jinf.2021.12.044

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.